Navigation Links
Reliance Products and Procter & Gamble Announce EPA Approval of New Claims for PUR Purifier of Water
Date:2/26/2009

WINNIPEG, Manitoba and CINCINNATI, Feb. 26, 2009 /PRNewswire/ -- Reliance Products LP and Procter & Gamble (NYSE: PG) announce that the U.S. Environmental Protection Agency (EPA) has approved new label claims for PUR(TM) Purifier of Water specific to the removal of arsenic, the parasites Cryptosporidium and Giardia, and cause-marketing language.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090115/CLTH035LOGO-a)

The EPA has approved the PUR(TM) Purifier of Water claim for:

-- The removal of greater than 98% of arsenic. Arsenic is odorless and tasteless and enters drinking water supplies from natural deposits in the earth or from agricultural and industrial practices. Arsenic has been linked to cancer of the bladder, lungs, skin, kidney, liver, and prostate.

-- The removal of greater than 99.9% of Cryptosporidium and Giardia, which are the two parasites of primary concern for drinking water quality. Cryptosporidium is very resistant to disinfection and has caused several large waterborne disease outbreaks of gastrointestinal illness in the U.S., including death in some immunocompromised people.

-- The cause-related marketing claims indicating that P&G will donate $0.10 for every PUR purchase. This level of donation is sufficient to provide 10 liters of safe drinking water in the developing world.

Reliance Products is the exclusive United States and Canada distributor of P&G's PUR(TM) Purifier of Water product, a powdered water clarification and disinfectant that comes in small, affordable, and easy-to-use packets. The product is designed for emergency preparedness use and situations where water is of unknown or questionable quality. Reliance retails both the
'/>"/>

SOURCE Procter & Gamble
Copyright©2009 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3

Related medicine news :

1. Please Dont Forget Me: Stories of the Survivors: New Spiritual Memoir Shares One Couples Reliance on God While Facing Adversity
2. Testimony to Congress Denounces FDA Reliance on Self-Policing
3. New Water Purification Product from Reliance Products and Procter & Gamble now Available in Retail Stores
4. BioReliance Appoints Executive Chairman to be Interim CEO and Announces Recent Senior Executive Additions
5. Experts Call for FDA Regulation of Tobacco Products
6. RBC Life Sciences 2008 Net Sales Increase 13 Percent as Its Nutritional Supplements and Medical Products Brands See Continued Growth
7. Command Medical Products, Inc. Welcomes James Carnall
8. Solos Endoscopy, Inc.s MammoView(TM) Featured in December Issue of Surgical Products Magazine
9. Precautionary Allergy Alert on Undeclared Milk Protein in Expired Codes of Broughton Foods Pints of Orange Juice, Citrus Punch, Fruit Punch and Iced Tea Products
10. PAREXEL Consulting Enhances European Regulatory Affairs Capabilities With Appointment of Medical Products Agency Expert Dr. Anders Neil
11. DRE Adds Professionally Refurbished Endoscopy Products to Online Catalog
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine Technology:Allos Therapeutics' PDX Granted Orphan Medicinal Product,Designation by the European Commission 2Allos Therapeutics' PDX Granted Orphan Medicinal Product,Designation by the European Commission 3Allos Therapeutics' PDX Granted Orphan Medicinal Product,Designation by the European Commission 4Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 2Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 3Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 4Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 5Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 6Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 7Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 8